Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q4 FY2026 Earnings Presentation
37 slides from Gufic Biosciences's earnings presentation, May 29, 2026
Slide 1: Investor Presentation cover letter to exchanges
139/LG/SE/MAY/2026/GBSL May 29, 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presentatio
Slide 2: Delivering Care & Cure Investor Presentation Q4FY2026
Delivering Care & Cure Investor Presentation For Q4FY2026
Slide 3: Safe Harbor
Safe Harbor This presentation has been pr epar ed by and is the sole r esponsibility of Gufic B iosciences Limi ted (the “ Com pany” ). By accessing this pr ese ntation, you ar e agr eeing to be bound by the tr ailing re str ictions. This pr esentation does not constitute or form part of any offer o
Slide 4: Q4 FY26 Business & Financial Highlights
Q4 FY26 Business & Financial Highlights
Slide 5: Indore Facility update: Progress on track as planned
Indore Facility update: Progress on track as planned We have built one of the most advanced lyophilized Timeline of our phased approach injectable facilities, commenced production in Milestone Target Status & Commentary October 2024 Installation & Operational ✅ Completed – facility meets WHO GMP, EU
Slide 6: At peak utilization, Indore alone can generate approximately Rs 675–700 Cr of revenue
At peak utilization (75%+), Indore alone can generate approximately Rs 675–700 Cr of revenue from domestic + export pull-through FY26 Quarterly Execution Gufic Advantage What We Delivered Quarter by Quarter Fully Integrated Injectable Platform Quarter Milestone Detail / Evidence Barrier Why It Matte
Slide 7: I. Hospital Injectable Platform
I. Hospital Injectable Platform. Therapy Focus: Anti-Microbials, Immunology & Cardiac Critical Care A. Critical Care Cluster B. Sparsh Hospital-first execution to widen ICU account coverage and compound molecule- Scaling a hospital + nursing-home platform by tightening execution infrastructure and c
Slide 8: Complex injectable pipeline for the hospital platform
Complex injectable pipeline for the hospital platform Drug Class Unique Advantages Complexity in Manufacturing Domestic Business Breakup Novel β-lactam/β- Targets multi-drug resistant Gram-negative Complex formulation with dual agents requires precise lactamase Inhibitor bacteria; highly effective f
Slide 9: II. Women's Health Platform
II. Women’s Health Platform. Therapy Focus: Assisted Reproductive Technology(IVF), Immunology & Ortho-gynae A. Ferticare Cluster B. Zenova Scaling a high-science fertility franchise by owning Reproductive Immunology and Upgrading portfolio quality by scaling prescription-led power brands, expanding
Slide 10: III. Botulinum Toxin Platform
III. Botulinum Toxin Platform. Therapy Focus: Aesthetics & Neurology A. Aesthaderm B. Neurocare Scaling from a toxin brand into a full-stack aesthetics platform by widening Scaling the Therapeutic Toxin Franchise by creating new injectors in guideline- injector creation, strengthening evidence, and
Slide 11: IV. Nutra, Ayurveda & Others
IV. Nutra, Ayurveda & Others. Therapy Focus: Chronic Musculoskeletal Pain & Gastro Nutra, Ayurveda & Others Repositioning the portfolio as a science-led chronic-care platform in pain, arthritis and GI—driving sustainable reach through differentiated formulations and next-gen prescriber ecosystem bui
Slide 12: V. International Business
V. International Business: Shifting international growth from opportunistic filings to an IP-owned, complex- injectables-led export & licensing engine. Strategy: Why We Changed the Model Regulatory update for Q4 FY2026 Gufic's international business historically was a distributor-led, opportunistic-
Slide 13: V. Near Term Indore Scale Up Plan
V. Near Term Indore Scale Up Plan: Converting complex injectables expertise into a global sales and licensing engine. RA Status--> Key Products with Stringent Countries-Ready Dossiers Strategic Roadmap (3–5 Years) Regulated Market Current Market Size Market Share Goal: Capture 5–10% in identified
Slide 14: Gufic's R&D Focus
Gufic’s R&D Focus: Peptides & Critical API Self-Reliance Novel Drug Delivery Systems (NDDS) Clinical Programs 13
Slide 15: Research & Development
Research & Development C. API Development — Reducing Supply Chain Dependence A. Peptides & Critical API Self-Reliance API Category Strategic Goal Gufic is building in-house peptide API development capability — Develop in-house to reduce Chinese dependence for reducing dependence on Chinese API suppl
Slide 16: Research & Development: Clinical Programs
Research & Development Clinical Programs — 17 Active/Pipeline Studies Phase Count Therapy Areas Reproductive immunology (Guficin Alpha/RIF), Botulinum Toxin Ongoing Clinical 5 (Aesthaderm), Gonadotropin (Puregraf), Wound healing, Phase III Trials biosimilar (rFSH ) Pipeline Clinical NDDS formats, wo
Slide 17: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 18: Profit & Loss Statement
Profit & Loss Statement Particulars Q4 FY26 Q3 FY26 Q4 FY25 FY26 FY25 (in Rs. Crore) Total Revenue 252.1 231.1 205 940.5 819.8 EBITDA 44.7 37.1 27 152.9 138.6 EBITDA Margin % 17.73% 16.05% 13.17% 16.26% 16.91% Profit before Tax 27.6 21.1 10.8 85.5 94.4 PBT Margins % 10.95% 9.13% 5.27% 9.09% 11.52% T
Slide 19: Company Overview
Company Overview
Slide 20: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas INTERNATIONAL B
Slide 21: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Natural Products (Topical/Liquid) Amphoter
Slide 22: New Manufacturing Infrastructure
New Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Commercial Production Achieved Facility Carbapenems (Lyophilized / Dry Capability to cater to regulated Powder Inj / Oral Solids / Dual markets such as
Slide 23: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 24: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s 200+ Field Force: 250 Therapy Areas: Antibacterial, Field Force: >150 Therapy Areas: Hormones, Field Force: >180 Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 25: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 26: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 27: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 28: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 29: Extensive Sales, Distribution and IT Infrastructure
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure 23 Carrying & Forwarding Retail coverage of more than (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 30: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 31: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 32: Historical Financials
Historical Financials
Slide 33: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Total Income 943.1 823.4 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 152.9 138.6 149.5 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 16.21% 16.83% 18.48% 19.79% 19.31% 17.85% 15.05% 15.77% Profit before Tax 85.4 94.4 11
Slide 34: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 10 10 9.7 9.7 9.7 9.7 7.8 Other Equity 654.2 591.3 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 664.2 601.3 532.5 347.8 269.1 173.4 129.3
Slide 35: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 467.1 475.2 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 6.2 6.3 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 22.1 21.8 307.1 169.6 4
Slide 36: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 85.5 94.4 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 65.2 43.8 34.1 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before workin
Slide 37: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000